T2 Biosystems (TTOO) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $2.0 million, up 34% year-over-year, driven by strong sepsis test and U.S. T2Bacteria Panel sales, as well as international instrument growth.

• Net loss for Q3 2024 was $10.1 million ($0.57 per share), improved from $15.4 million ($3.45 per share) in Q3 2023.

• Exclusive U.S. distribution agreement signed with Cardinal Health and co-marketing collaboration with Precision Inc. to integrate AI-powered stewardship with rapid diagnostics.

• FDA clearance received for T2Candida Panel for pediatric patients in September 2024; pipeline progress includes FDA breakthrough designations and new product launches planned for 2025.

• Substantial doubt exists about the ability to continue as a going concern without additional funding in Q4 2024.

Financial highlights

• Q3 2024 revenue was $2.0 million, all from sepsis products, a 34% increase from the prior year.

• International instrument sales rose 78% year-over-year; U.S. T2Bacteria Panel sales grew 173%.

• Cost of product revenue for Q3 2024 was $4.1 million, up 4% year-over-year; gross margin remained negative.

• Net loss for the nine months ended September 30, 2024, was $32.6 million, compared to $39.7 million in the prior year period.

• Cash and equivalents stood at $2.1 million as of September 30, 2024; $4.3 million raised via ATM during the quarter, $3.2–$3.3 million since quarter-end.

Outlook and guidance

• Q4 2024 sepsis and product revenues expected between $2.5 million and $3.5 million, excluding potential T2 Biothreat or T2 Lyme test sales.

• Cardinal Health partnership anticipated to significantly impact U.S. sales in 2025, with some effect possible in late 2024.

• T2 Lyme Panel LDT launch targeted for late Q2 2025, expected to contribute to first-half 2025 revenue.

• T2 Resistance Panel FDA submission planned for Q1 2025.

• Management believes current cash is insufficient to fund operations for 12 months; additional financing is required in Q4 2024.